Prof Paul Johnson and his Islet Transplant Research Group have been awarded Horizon 2020 Funding as part of the DRIVE Consortium to evaluate and develop novel biomaterials and macroencapsulation strategies for transplanting islets without immunosuppression. This new award adds to their current FP7 European Funding, in which the Group has been evaluating and optimising islet function and survival within the MAILPAN (Deymed) device, with 'first in man' implantation planned in Oxford for 2016.